Severe proteinuria during the administration of bevacizumab plus mFOLFOX6 in a colorectal cancer patient after kidney transplantation: a case report
Abstract Background Bevacizumab (BEV) leads to proteinuria and renal damage. It is not clear whether the administration of immunosuppressive drugs after renal transplantation affects the safety of BEV administration. We report a case of severe proteinuria caused by BEV plus 5-fluorouracil, levofolin...
Main Authors: | Ren Onodera, Satoru Nihei, Toshimoto Kimura, Takashi Tomita, Kenzo Kudo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Journal of Pharmaceutical Health Care and Sciences |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40780-020-00175-7 |
Similar Items
-
Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study
by: Satoru Nihei, et al.
Published: (2024-08-01) -
Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria
by: Emmanouil Saloustros, et al.
Published: (2010-10-01) -
Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study
by: Guohu Han, et al.
Published: (2023-12-01) -
Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
by: Yuta Ushida, et al.
Published: (2018-08-01) -
Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)